CML Treatment – Chronic Myeloid Leukemia Treatment


Omacitaxine belongs to a family of drugs called protein translation inhibitors, meaning that they stop the cell from replicating by preventing the formation of proteins formed from the defective DNA. It can be given in cases resistant to multiple tyrosine kinase inhibitors, but it has a bad profile of side effects including anemia, infections, and low platelet count in more than half of the patients receiving it, so it is considered as a last resort before stem cell transplantation.